{
    "clinical_study": {
        "@rank": "148221", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Assess the clinical response of patients with refractory or recurrent brain neoplasms\n      treated with carmustine, streptozocin, and mercaptopurine."
        }, 
        "brief_title": "Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms", 
        "condition": [
            "Anaplastic Astrocytoma", 
            "Anaplastic Oligodendroglioma", 
            "Mixed Gliomas", 
            "Glioblastoma Multiforme", 
            "Recurrent Brain Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Astrocytoma", 
                "Brain Neoplasms", 
                "Glioblastoma", 
                "Glioma", 
                "Oligodendroglioma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Patients receive mercaptopurine IV on days 1-3, carmustine by continuous infusion on days\n      3-5, and streptozocin IV over 20 minutes on days 2-5. Patients receive treatment every 42\n      days, for up to 4 courses."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Histologically proven refractory or recurrent brain neoplasms\n        Glioblastoma multiforme Anaplastic astrocytoma Gliosarcoma Anaplastic oligodendroglioma\n        Mixed anaplastic glioma Unequivocally progressive primary brainstem tumors following\n        primary therapy Measurable disease --Prior/Concurrent Therapy-- Biologic therapy: Not\n        specified Chemotherapy: At least 4 weeks since prior chemotherapy At least 6 weeks since\n        prior nitrosoureas or mitomycin Endocrine therapy: Not specified Radiotherapy: Prior\n        radiotherapy allowed Surgery: Prior surgery allowed --Patient Characteristics-- Age: Not\n        specified Performance status: ECOG 0-2 Karnofsky 60-100% Hematopoietic: Granulocyte count\n        at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than\n        2.0 mg/dL SGOT no greater than 4 times normal Renal: Creatinine no greater than 2.0 mg/dL\n        Pulmonary: FEV1 greater than 1 L if symptomatic pulmonary disease present Other: No other\n        concurrent malignancies Not pregnant or lactating Negative pregnancy test Fertile patients\n        must use effective contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "35", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004688", 
            "org_study_id": "199/13310", 
            "secondary_id": "EUSM-FDR001274"
        }, 
        "intervention": [
            {
                "intervention_name": "carmustine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "mercaptopurine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "streptozocin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "6-Mercaptopurine", 
                "Carmustine", 
                "Streptozocin"
            ]
        }, 
        "keyword": [
            "adult anaplastic astrocytoma", 
            "adult anaplastic oligodendroglioma", 
            "adult brain stem glioma", 
            "adult brain tumor", 
            "adult glioblastoma multiforme", 
            "adult infiltrating astrocytoma", 
            "brain tumor", 
            "genetic condition", 
            "miscellaneous sites/terms", 
            "mixed gliomas", 
            "nervous tissue tumors", 
            "oncologic disorders", 
            "rare disease", 
            "recurrent adult brain tumor"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Emory University", 
            "last_name": "Mark R. Gilbert", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004688"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Emory University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "August 1996", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1999"
    }, 
    "geocoordinates": {}
}